Leerink Partners Starts Metsera Inc (MTSR) at Outperform

Leerink Partners analyst David Risinger initiates coverage on Metsera Inc (NASDAQ: MTSR) with a Outperform rating and a price target of $77.00.

The analyst comments "We are initiating coverage of MTSR with an Outperform rating and a PT of $77, based upon DCF valuation. Our investment thesis is that the company’s platform and pipeline of novel obesity peptide-based therapeutics offer key advantages relative to competing assets. We believe that Wall Street underappreciates the company’s monthly injectable GLP-1, monthly injectable amylin, daily oral GLP-1 peptide, and peptide manufacturing peptide scale advantages relative to competitors. We would also highlight that the company is led by highly experienced executives with strong track records, including Chairman Clive Meanwell, CEO Whit Bernard, CFO Chris Visioli, CSO Brian Hubbard, and Chief Development Officer Peter Wijngaard."

For an analyst ratings summary and ratings history on Metsera Inc click here. For more ratings news on Metsera Inc click here.

Shares of Metsera Inc closed at $35.10 yesterday.

You May Also Be Interested In

• Uniti Group (UNIT) 3700 contracts of July 13 calls trade, share up 7%
• General Dynamics (GD) call put ratio 6.2 calls to 1 put as share price up 6.3%
• Golden Sky Minerals Receives Government Notification of Advancing Infrastructure Near Lucky Strike Property